MTOR and diabetes mellitus: Research evidence has demonstrated that dysregulation of the mechanistic target of rapamycin (mTOR) signaling axis is involved in disease onset covering a broad spectrum of conditions from diabetes to various tumor types as well as inflammatory skin disorders and skin cancers.